E Educator New member Wednesday at 9:47 AM #1 The FLOW trial demonstrated that semaglutide significantly improves kidney and cardiovascular outcomes in people with chronic kidney disease and type 2 diabetes, irrespective of SGLT2 inhibitor use.
The FLOW trial demonstrated that semaglutide significantly improves kidney and cardiovascular outcomes in people with chronic kidney disease and type 2 diabetes, irrespective of SGLT2 inhibitor use.